AmnioAMP-WJ™
Wharton’s Jelly Allograft
Harness the innate power of the human body
CellGenuity develops biologics designed to be used as a therapeutic agent. Formulated with our patented PūrAMP Process™, our products are used in a wide range of surgical and non-surgical applications.
AmnioAMP-WJ™
Wharton’s Jelly Allograft
AmnioAMP-WJ™ contains isolated Wharton’s Jelly derived from the umbilical cord that provides cushioning and support to the umbilical vein and arteries. Wharton’s Jelly does not exhibit an immune reaction or rejection, considered “immune privileged”. Our proprietary PūrAMP Process™ does not alter the original tissue’s function as a Wharton’s Jelly connective tissue, providing physical support and cushioning. AmnioAMP-WJ™ is regulated as human cell, tissue or cellular-tissue based product (HCT/P) 21 CFR Part 1271.10 and 361 of the Public Health Service Act. This is regulated as human cell product-for homologous use only.
Advantages
Cryopreserved for the ultimate biological viability.
Provided in an easy to apply flowable form, for precise delivery to the intended site.
Contained in a sterile vial ready to be introduced to the sterile field.
Can be applied with a 25 gauge needle.
Features
AminoAMP-WJ™ contains a higher concentration of long chain hyaluronic acid, and growth factors².
AmnioAMP-WJ is minimally manipulated to preserve the biological components of Wharton’s Jelly¹.
Delivered pre-packaged with dry ice for optimal storage.
Wharton’s Jelly provides cushioning, support and lubrication; Wharton’s Jelly is the only biologic which has the structure to perform these functions.
- U.S. Food and Drug Administration. Minimal manipulation of human cells, tissues, and cellular-based products: draft guidance.
- Bauer SM, Bauer RJ, Velazquez OC. Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. Vasc Endovascular Surg: 2005;39:293-306. doi: 10.177/15385744050300401. – DOI – PubMed